Medicenna Therapeutics (MDNAF)
(Delayed Data from OTC)
$0.70 USD
+0.02 (2.50%)
Updated Sep 26, 2025 03:00 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDNAF 0.70 +0.02(2.50%)
Will MDNAF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MDNAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDNAF
Medicenna Therapeutics (MDNAF) Upgraded to Buy: Here's What You Should Know
MDNAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MDNAF
Medicenna Therapeutics Announces Shareholder Meeting Results and Leadership Updates
Medicenna Therapeutics Corp. (MDNA:CA) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow
Medicenna to Present at H.C. Wainwright Global Investment Conference
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference | ...
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational ...